[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA55597A - Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif - Google Patents

Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif

Info

Publication number
MA55597A
MA55597A MA055597A MA55597A MA55597A MA 55597 A MA55597 A MA 55597A MA 055597 A MA055597 A MA 055597A MA 55597 A MA55597 A MA 55597A MA 55597 A MA55597 A MA 55597A
Authority
MA
Morocco
Prior art keywords
thiazolides
nitazoxanide
treatment
oxidative stress
diseases associated
Prior art date
Application number
MA055597A
Other languages
English (en)
Inventor
Corinne Foucart
Peggy Parroche
Nicolas Stankovic-Valentin
Robert Walczak
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MA55597A publication Critical patent/MA55597A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58Nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA055597A 2019-04-12 2020-04-09 Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif MA55597A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19305480 2019-04-12

Publications (1)

Publication Number Publication Date
MA55597A true MA55597A (fr) 2022-02-16

Family

ID=66334322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055597A MA55597A (fr) 2019-04-12 2020-04-09 Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif

Country Status (10)

Country Link
US (1) US20220193042A1 (fr)
EP (1) EP3952869A1 (fr)
JP (1) JP2022528727A (fr)
KR (1) KR20210151854A (fr)
CN (1) CN113710247A (fr)
AU (1) AU2020271636A1 (fr)
BR (1) BR112021020496A2 (fr)
CA (1) CA3130518A1 (fr)
MA (1) MA55597A (fr)
WO (1) WO2020208208A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000754A1 (en) * 2020-11-17 2024-01-04 Genfit Methods of treatment of liver failure
CN112957358A (zh) * 2021-04-01 2021-06-15 北京大学第三医院(北京大学第三临床医学院) 硝唑尼特及其衍生物在制备预防和治疗骨破坏性疾病药物中的用途
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
CA2836253C (fr) * 2011-05-16 2021-02-16 Romark Laboratories, L.C. Utilisation de composes thiazolides pour la prevention et le traitement d'infections virales, du cancer et de maladies causees par des infections intracellulaires
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2017178174A1 (fr) * 2016-04-11 2017-10-19 Genfit Méthodes de traitement de la cholestase et de la fibrose
JP6894923B2 (ja) * 2016-04-11 2021-06-30 ジェンフィGenfit 胆汁うっ滞性及び線維性の疾患の処置方法
US10653678B2 (en) * 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
CA3046158A1 (fr) * 2017-01-27 2018-08-02 Genfit Compositions pharmaceutiques pour polytherapie
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물

Also Published As

Publication number Publication date
US20220193042A1 (en) 2022-06-23
CA3130518A1 (fr) 2020-10-15
EP3952869A1 (fr) 2022-02-16
CN113710247A (zh) 2021-11-26
JP2022528727A (ja) 2022-06-15
AU2020271636A1 (en) 2021-11-04
WO2020208208A1 (fr) 2020-10-15
BR112021020496A2 (pt) 2021-12-07
KR20210151854A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
MA49458A (fr) Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
MA55597A (fr) Nitazoxanide et thiazolides destinés à être utilisés dans le traitement de maladies associées au stress oxydatif
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
IL262608A (en) Combined treatment of eye disorders and inflammatory diseases
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA56392A (fr) Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA47503A (fr) Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
MA56047A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
EP4009948A4 (fr) Utilisation de polypeptides tgf-alpha ou d'anticorps anti-tgf-alpha pour le traitement de maladies et de troubles
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EP3969125A4 (fr) Utilisation d'anticorps anti-fcrn dans le traitement du pemphighus et de maladies du pemphigoïde
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
IL286268A (en) Pridopidine for the treatment of mitochondrial diseases and disorders and symptoms associated with these diseases
IL285452A (en) A new recombinant diamine oxidase and its use in the treatment of diseases characterized by excess histamine
MA55507A (fr) Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire
MA54936A (fr) Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
MA51128A (fr) Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IL276138A (en) Anticoagulant proteins and their uses in the treatment of diseases associated with the activation of neutrophils